Geoff MacKay is President and CEO of Avrobio Inc, a clinical stage cell and gene therapy company based in Cambridge MA. The company focus is in rare disease and immune-oncology.
He is also interim CEO and Director of eGenesis Inc., which applies CRISPR-Cas 9 gene editing to the field of xenotransplantation.
Mr MacKay spent 11 years as President and Chief Executive Officer at Organogenesis Inc., building the company into the leading regenerative medicine company in the world as measured by FDA approvals, patients treated and revenue.
Mr. MacKay held numerous leadership positions within Novartis AG, such as Vice-President and Business Unit Head, Transplantation and Immunology at Novartis Canada, Vice-President of Tissue-Engineering in Novartis USA, Head of Global Sales Immunology and Transplantation based in Basel, Switzerland, and Sales and Marketing Manager of Novartis Biotech Europe.
Mr. MacKay has served as Chairman of the Board of the Alliance for Regenerative Medicine (ARM), a Washington DC-based multi-stakeholder advocacy group whose mission is to advance the field of regenerative medicine. ARM’s 200 members include companies, academic research institutions, patient advocacy groups, foundations, health insurers and investors dedicated to improving patients’ lives through regenerative medicine therapies.
Additionally, he is an Advisory Council member for the Health Policy Commission (HPC) for the Commonwealth of Massachusetts, a state agency that monitors the reform of the healthcare delivery and payment systems in Massachusetts, and develops health policy to reduce overall cost growth while improving the quality of patient care.
Through his public and private enterprise work, Mr. MacKay is dedicated to applying innovation to reshape and improve the current quality of healthcare.